FDA clears sacroiliac joint fusion device from Nevro
Nevro announced today that the FDA cleared its sacroiliac (SI) joint fusion device without the need to include an accompanying screw.
Stay updated with breaking news from Vyrsa Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Nevro announced today that the FDA cleared its sacroiliac (SI) joint fusion device without the need to include an accompanying screw.
Nevro earned FDA 510(k) clearance to use its sacroiliac joint fixation system without having to include a lateral screw, the devicemaker said Feb. 28.
Nevro Corp. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.5. Nevro Corp.
Q4 and Full-Year 2023 Earnings Highlight Execution of Three-Pillar Strategy
Pain-treatment device company Nevro is letting go of 63 employees, about 5% of its workforce, as part of a restructuring effort.